Skip to content

Screening of lung cancer/ esophageal cancer tumor markers based on metabolomics

Screening of lung cancer/ esophageal cancer tumor markers based on metabolomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021747
Enrollment
Unknown
Registered
2019-03-07
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer/ esophagus cancer

Interventions

Gold Standard:Pathological examination
tumor&#32

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Male or female, aged 18 years and above; (2) The subject reads and fully understands the instructions of the patient and signs the informed consent; (3) In the normal control group, postoperative pathological diagnosis was made for patients with bullae and benign lung lesions (non-tumor); (4) Patients in the tuberculosis group were initially diagnosed with pulmonary nodules and diagnosed with tuberculosis after nodulectomy; (5) Patients in the lung cancer group were initially diagnosed as pulmonary nodules and diagnosed as lung cancer after nodulectomy; (6) The esophageal cancer group was newly diagnosed with esophageal cancer pathologically, without any anti-tumor treatment.

Exclusion criteria

Exclusion criteria: (1) Patients with other malignant tumors; (2) Patients with severe metabolic diseases; (3) Emergency treatment or patient rescue; (4) Pregnancy.

Design outcomes

Primary

MeasureTime frame
Tumor biomakers;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactYuan Yunchang
yuanyunchang1405@126.com+86 13973121165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026